IDEA GENERATION

Global Pharma & GLP-1 Value Chain

Stock Screening & Thematic Sweep — Focus: NVO

2026-04-21

1. Screening Methodology

We screened the global pharmaceutical universe and GLP-1 value-chain complex using complementary approaches: (1) Value screen — large-cap pharma trading below 5-year average multiples with defensible FCF; (2) Quality / moat screen — ROIC leaders, durable franchises, high-barrier manufacturing; (3) Growth screen — exposure to GLP-1 volume expansion (incretins, obesity, MASH, CKD) directly or via value-chain services; (4) Thematic sweep — GLP-1 adjacencies including CDMOs (fill-finish capacity), device makers (pens, autoinjectors), and disruption-at-risk names (diabetes complications, bariatric, cardio).

Universe: 40+ names spanning large-cap pharma (NVO, LLY, MRK, PFE, AZN, BMY, SNY, RHHBY, GSK, ABBV), GLP-1 pipeline biotechs (VKTX, SRRK, GPCR, ALT, AMGN), CDMO/manufacturing (Samsung Biologics, Lonza, WuXi Bio), devices (BDX, BD, YPSN), and GLP-1 disruption-exposed names (DXCM, DOC, ISRG for bariatric, EW, ABT, NOVO's own peers). Direction is long + short.

2. Quantitative Screen Results

2.1 Value Screen — De-Rated Pharma Large-Cap

Pharma names trading >20% below 5-year average EV/EBITDA, with positive FCF and net leverage <2.5x. This screen isolates mean-reversion candidates among scaled, profitable franchises:

NVO emerges as the most materially de-rated franchise in global pharma — lowest multiple among growth-retaining peers.

2.2 Quality Screen — ROIC / Franchise Durability

Ranked by 5-year average ROIC, operating margin, and FCF conversion:

NVO remains the pharma ROIC leader at 52%. Franchise quality metrics demonstrate the de-rating is multiple compression, not earnings collapse.

2.3 Growth Screen — GLP-1 Value Chain

Companies with direct revenue exposure to GLP-1 class growth — whether as drug developer, CDMO supplier, device maker, or adjacent-therapy franchise:

2.4 Short / Disruption-at-Risk Screen

Names whose fundamentals face secular pressure from GLP-1 adoption. Evaluated for short-side risk/reward with consideration of counter-narratives:

Short conclusions: The GLP-1-disruption-short thesis has not delivered on any of these names in 2024-2025 (underlying demand resilient). We avoid fresh shorts here.

3. Thematic Sweep — GLP-1 Value Chain

The GLP-1 opportunity is diffusing beyond the two originators. We map the value chain to identify differentiated risk/reward:

3.1 Tier 1: The Originators (duopoly)

• Novo Nordisk (NVO): #1 by revenue, losing share, de-rated. Pipeline binary on CagriSema/amycretin.
• Eli Lilly (LLY): #1 by efficacy + pipeline, full valuation at 34x P/E. Retatrutide Phase 3 is the dominant catalyst.

3.2 Tier 2: Potential Next-Gen Entrants

• Viking (VKTX): VK2735 (oral + SC) Phase 2. M&A optionality — could be acquired by a Tier-1 lacking GLP-1 (PFE, BMY, ABBV, GSK).
• Structure (GPCR): Aleniglipron oral small molecule Phase 2b.
• Altimmune (ALT): Pemvidutide (GLP-1/glucagon) Phase 2b; MASH readout 2H 2025.
• Roche (RHHBY): CT-388 (via Carmot acquisition 2023) Phase 2 dual agonist.
• Amgen (AMGN): MariTide (unique mechanism — GIP antagonist/GLP-1 agonist), monthly dosing differentiation.

3.3 Tier 3: Manufacturing & Devices (picks-and-shovels)

• Ypsomed (YPSN-CH): Dominant autoinjector supplier to NVO and LLY. Capacity-constrained; structural tailwind.
• SHL Group (private): Alternative pen supplier.
• Samsung Biologics / Lonza / Siegfried / WuXi Bio: Peptide manufacturing; capacity expansion cycles.
• NVO's Catalent integration: Internal rather than third-party — eliminates LLY's option to use Catalent as a dual source.

3.4 Tier 4: Adjacent Revenue Streams

• Pre-filled syringe and vial: Schott, Gerresheimer, West Pharmaceutical (WST).
• Cold chain logistics: Cryoport, Marken.
• Patient software/telehealth: Noom, Hims (HIMS), Ro (private), Teladoc — direct channels but margin-compressed by compounding arbitrage.

4. Shortlist — Top 5 Ideas

From the screens and thematic work, five names rise as differentiated risk/reward. NVO is the primary focus of this initiation:

4.1 NVO — Novo Nordisk (Primary Focus)

• Thesis: De-rated from 32x to 12.5x P/E in 18 months. Semaglutide franchise still generates US$35B growing HSD. Amycretin pipeline could restore competitive positioning in 2027. Label expansion (MASH, CKD, OSA) + EM volume provides non-share-dependent growth.
• Metrics: US$44B revenue 2025E, 44% op margin, 52% ROIC, 0.7x ND/EBITDA, 2.7% dividend yield.
• Catalysts: amycretin Phase 2b (2H 2026), CagriSema launch (2026), MASH approval (2H 2026), Q1 2026 earnings (May 2026).
• Key risks: Retatrutide Phase 3 success; orforglipron launch; IRA 2027 pricing; amycretin failure.

4.2 LLY — Eli Lilly (Pair / Relative)

• Thesis: Class leader by efficacy and pipeline. Retatrutide is the single most important asset in pharma. Premium valuation justified if retatrutide confirms, overvalued if it stalls.
• Metrics: US$51B revenue 2025E (+35%), 42% op margin, 34x P/E.
• Use: Consider pair against NVO to hedge class-wide GLP-1 risk, though efficacy delta argues for maintaining LLY long exposure.

4.3 VKTX — Viking Therapeutics (Asymmetric)

• Thesis: VK2735 (dual GLP-1/GIP, oral + SC) Phase 2 data has shown efficacy competitive with tirzepatide. Binary — M&A target or standalone commercialization.
• Metrics: US$13B market cap, no revenue, US$950M cash runway.
• Catalysts: VK2735 oral Phase 2 data (2H 2026), VENTURE-oral obesity registration trial start.
• Risks: Clinical failure (binary); dilution if not acquired.

4.4 YPSN-CH — Ypsomed (Picks-and-Shovels)

• Thesis: Dominant autoinjector supplier to NVO/LLY; capacity-constrained with multi-year order book. Indirect GLP-1 exposure without clinical risk.
• Metrics: CHF 4B market cap, ~18% revenue growth 2025E, 22% op margin.
• Catalysts: Capacity expansion (Germany, Czech Republic facilities).
• Risks: Customer concentration (>70% from NVO/LLY); generic pen-refill exposure post-2032.

4.5 RHHBY — Roche (Value / Optionality)

• Thesis: Trading at 10x EV/EBITDA with underappreciated CT-388 GLP-1 asset + broad oncology + diagnostics. Phase 2 CT-388 data expected 2026; success would re-rate multiples.
• Metrics: CHF 210B market cap, US$67B revenue, 31% op margin, 4.1% dividend yield.
• Catalysts: CT-388 data; oncology pipeline (Vabysmo, Phesgo).
• Risks: Currency (CHF), BioCeros biosimilar competition, Asia/China pricing.

5. Shortlist Comparison

6. Prioritization & Next Steps

• Priority 1 — NVO: Proceed to full initiation. Valuation de-rating provides margin of safety; pipeline binary readouts are near-term; franchise fundamentals remain elite. This report's full pipeline (comps, DCF, 3-statements, initiation report) focuses here.
• Priority 2 — LLY: Monitor for pair-trade setup post retatrutide Phase 3. Not adding as fresh long at 34x P/E.
• Priority 3 — VKTX: Size as asymmetric biotech bet within a separately allocated sleeve. Monitor dose-escalation data Q4 2026.
• Priority 4 — YPSN: Attractive secondary exposure; revisit when Swiss mid-cap liquidity improves and customer diversification reaches >35%.
• Priority 5 — RHHBY: Defensive pharma with CT-388 optionality; suitable as pair against NVO to hedge class-specific risk.

DISCLAIMER: This report was produced by an agentic AI workflow (Agentic Finance Chile) for research and educational purposes. Data current to Apr 2026. Not investment advice.